Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio post-approvazione del sistema stent-graft addominale TREO (TREO PAS)

10 novembre 2026 aggiornato da: Bolton Medical

Studio post-approvazione del sistema stent-graft addominale TREO (P190015) in pazienti con aneurismi dell'aorta addominale infrarenale e dell'aorto-iliaco

The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a prospective, multi-center, non-randomized, single-arm, post-market, non-interventional study of treatment with the TREO Abdominal Stent-Graft in subjects with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms. The study will include a minimum of 300 subjects treated with the TREO Abdominal Stent-Graft at up to 55 investigational sites in the US.

The primary objective is the collection of real world safety and effectiveness outcomes of the TREO Abdominal Stent-Graft System in an all-comers population eligible for the endovascular treatment of AAA in routine clinical practice, with emphasis on subjects that experience a device stent-strut or barb fracture.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

338

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85006
        • Vascular Surgery Specialists
      • Tucson, Arizona, Stati Uniti, 85718
        • Pima Heart and Vascular
    • California
      • Fresno, California, Stati Uniti, 93701
        • University of California, San Francisco-Fresno
      • La Jolla, California, Stati Uniti, 92037
        • University of California, San Diego
      • San Diego, California, Stati Uniti, 92161
        • VA San Diego
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80045
        • University of Colorado Anschutz
    • Connecticut
      • New Haven, Connecticut, Stati Uniti, 06520
        • Yale University
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20010
        • Medstar Washington Hospital Center
    • Florida
      • Gainesville, Florida, Stati Uniti, 32610
        • University of Florida
      • Gainesville, Florida, Stati Uniti, 32608
        • Malcom Randall VA Medical Center
      • Pensacola, Florida, Stati Uniti, 32504
        • Coastal Vascular and Interventional
      • Tampa, Florida, Stati Uniti, 33606
        • University of South Florida / Tampa General Hospital
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30342
        • Northside Hospital
      • Atlanta, Georgia, Stati Uniti, 30309
        • Piedmont Heart Institute
    • Iowa
      • Iowa City, Iowa, Stati Uniti, 52242
        • University of Iowa Hospital and Clinic
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
        • Massachusetts General Hospital
      • Boston, Massachusetts, Stati Uniti, 02111
        • Tufts Medical Center
    • Michigan
      • Bay City, Michigan, Stati Uniti, 48708
        • McLaren Bay Region
      • Detroit, Michigan, Stati Uniti, 48202
        • Henry Ford Hospital
    • Minnesota
      • Minneapolis, Minnesota, Stati Uniti, 55407
        • Minneapolis Heart Institute Foundation
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110
        • Barnes Jewish Hospital at Washington University
    • New Jersey
      • Hackensack, New Jersey, Stati Uniti, 07601
        • Hackensack University Medical Center
      • New Brunswick, New Jersey, Stati Uniti, 08901
        • Rutgers Robert Wood Johnson Medical Center
    • New York
      • New York, New York, Stati Uniti, 10075
        • Lenox Hill Hospital / Northwell Health
      • Stony Brook, New York, Stati Uniti, 11794-8191
        • Stony Brook Medical Center
      • Syracuse, New York, Stati Uniti, 13210
        • SUNY Upstate Medical University
      • The Bronx, New York, Stati Uniti, 10467
        • Montefiore Medical Center
    • North Carolina
      • Asheville, North Carolina, Stati Uniti, 27607
        • Mission Health
      • Greenville, North Carolina, Stati Uniti, 27834
        • East Carolina University
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Portland, Oregon, Stati Uniti, 97239
        • Oregon Health and Science University
      • Portland, Oregon, Stati Uniti, 97239
        • VA Portland Healthcare System
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19140
        • Temple University Hospital
      • Pittsburgh, Pennsylvania, Stati Uniti, 15232
        • University of Pittsburgh Medical Center
    • Tennessee
      • Kingsport, Tennessee, Stati Uniti, 37660
        • Wellmont Cardiology Services
    • Texas
      • Austin, Texas, Stati Uniti, 78756
        • St. David's Healthcare (Cardiothoracic and Vascular Surgeons)
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84132
        • University of Utah Hospital
    • Virginia
      • Norfolk, Virginia, Stati Uniti, 22042
        • Sentara Heart Hospital
      • Richmond, Virginia, Stati Uniti, 23282
        • Virginia Commonwealth University
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Medical College of Wisconsin

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Willing and able to comply with all study procedures and visits.
  • Written informed consent to participate in the study.
  • Patient's aneurysm can be treated with the TREO Abdominal Stent-Graft System.
  • Adequate data (medical records/imaging studies) available to analyze the primary endpoints for patients enrolled retrospectively.

Exclusion Criteria:

• Medical, social or psychological problems that, in the opinion of the investigator, preclude patient from receiving treatment with the TREO Abdominal Stent-Graft System.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Subjects who receive the TREO Abdominal Stent-Graft System

Eligible subjects will be implanted with the TREO Abdominal Stent-Graft System.

The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of stent-strut fracture or barb separation as confirmed by the Imaging Core Laboratory.
Lasso di tempo: Through 5 Years post-procedure

Incidence of fracture in a stent-strut or separation of one or more proximal fixation barbs as confirmed by the Imaging Core Laboratory upon review of post-implant imaging studies.

Through 5 Years post-procedure
Incidence of secondary intervention for adverse events related to or caused as a result of stent-strut fracture or barb separation.
Lasso di tempo: Through 5 Years post-procedure

Incidence of secondary intervention for adverse events related to or caused as a result of a fracture in a stent-strut or separation of one or more proximal fixation barbs. Relatedness to the device will be confirmed by the Clinical Events Committee (CEC) through review of available treatment and procedure records and reports of imaging studies.

Through 5 Years post-procedure

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of participants with technical success at the conclusion of the index procedure
Lasso di tempo: Through 5 Years post-procedure

Defined as the following:

  • successful delivery (i.e., ability to deliver the implant to the intended location without the need for unanticipated corrective intervention related to delivery);
  • successful and accurate deployment (deployment of the endovascular stent graft in the planned location; patency of the endovascular stent graft, absence of device deformations such as kinks, stent eversion, mal-deployment, misaligned deployment, requiring unplanned placement of an additional device within the endovascular stent graft, and
  • successful withdrawal (i.e. successful withdrawal of the delivery system, without the need for unanticipated corrective intervention related to withdrawal)
Through 5 Years post-procedure
Major Adverse Events
Lasso di tempo: Through 5 Years post-procedure

Incidence of the following Major Adverse Events

  • Myocardial infarction according to SCAI definition
  • Stroke according to the VARC-2 guidelines
  • New Onset Renal Failure requiring permanent dialysis
  • New onset Respiratory Failure requiring permanent home oxygen therapy through 30 days
  • Permanent Paralysis/Paraplegia
  • Bowel Ischemia
  • Procedural blood loss (≥ 1000cc)
Through 5 Years post-procedure
Incidence of procedure-related clinical utility measures
Lasso di tempo: Through 5 Years post-procedure

Reporting of procedural data collected during implant of the TREO Abdominal Stent-Graft System including: Procedure time (minutes), Fluoroscopy time (minutes), Contrast volume (mL), Access method (i.e. percutaneous, surgical cut down), Length of ICU stay (hours), Length of hospital stay post-procedure (days), Anesthesia Type.

Through 5 Years post-procedure
Incidence of procedure-related complications
Lasso di tempo: Through 5 Years post-procedure

Incidence of adverse events occurring during or following the implant determined by the CEC to be procedure-related.

Through 5 Years post-procedure
Incidence of successful aneurysm treatment
Lasso di tempo: 12 months post-implant

Successful aneurysm treatment is defined as:

  • Technical success
  • Absence of death from the initial procedure, secondary intervention or aortic-related cause.
  • Absence of persistent type I or III endoleaks
  • Absence of aneurysm sac expansion >5 mm
  • Absence of device migration >10mm
  • Absence of failure due to device integrity issues
  • Absence of aneurysm rupture
  • Absence of conversion to open surgical repair
  • Absence of permanent paraplegia, disabling stroke or dialysis that resulted from the initial operation or a secondary intervention to treat the original aortic pathology.
12 months post-implant
Incidence of all-cause mortality
Lasso di tempo: Through 5 Years post-procedure

Rate of mortality attributed to any causality as confirmed by the CEC.

Through 5 Years post-procedure
Incidence of aneurysm-related mortality
Lasso di tempo: Through 5 Years post-procedure

Rate of mortality attributed to the following causes as confirmed by the CEC: death due to a rupture, death within 30 days or prior to hospital discharge from primary procedure, or death within 30 days or prior to hospital discharge for a secondary procedure designed to treat the original aneurysm.

Through 5 Years post-procedure
Incidence of aneurysm rupture
Lasso di tempo: Through 5 Years post-procedure

Incidence of rupture of the native aneurysm sac post-implantation of the endograft as confirmed by the CEC.

Through 5 Years post-procedure
Incidence of secondary interventions.
Lasso di tempo: Through 5 Years post-procedure

Incidence of secondary procedures designed to treat or repair the original aneurysm treated with the TREO Abdominal Stent-Graft System

Through 5 Years post-procedure
Incidence of conversion to open surgical repair.
Lasso di tempo: Through 5 Years post-procedure

Incidence of conversion to open surgical AAA repair during the initial EVAR procedure secondary to any procedure-related complications as determined by the CEC.

Through 5 Years post-procedure
Incidence of stent-graft occlusion (i.e., loss of patency)
Lasso di tempo: Through 5 Years post-procedure

Incidence of stent-graft occlusion defined as the unintentional obstruction of the vascular/endograft lumen with minor obstruction (0-25%), minimal obstruction (26-74%), moderate obstruction (75-99%) or occlusion (100%) as confirmed by the Imaging Core Lab due to causes such as twisting or kinking of the prosthesis, oversizing and fabric pleating, or failure of the implant to fully open, or to mural thrombus deposition.

Through 5 Years post-procedure
Incidence of device stenosis or kink
Lasso di tempo: Through 5 Years post-procedure

Incidence of stenosis or kinking of the TREO Stent-Graft as confirmed by the Imaging Core Lab.

Through 5 Years post-procedure
Incidence of loss of device integrity
Lasso di tempo: Through 5 Years post-procedure

Incidence of changes in the structural integrity in a material component of the stent-graft such as a stent-strut fracture or separation of the proximal fixation barbs as confirmed by the Imaging Core Lab.

Through 5 Years post-procedure
Incidence of aneurysm enlargement (>5mm as compared to 30-day imaging).
Lasso di tempo: Through 5 Years post-procedure

Incidence of the increase in the aneurysm sac diameter > 5 mm at post-implant follow-up visits relative to the diameter determined at the first post-procedural imaging study, as confirmed by the Imaging Core Lab.

Through 5 Years post-procedure
Incidence of stent-graft migration (>10mm as compared to 30-day imaging)
Lasso di tempo: Through 5 Years post-procedure

Incidence of the longitudinal movement of all or part of a stent or attachment system for a distance of >10 mm relative to anatomical landmarks that were determined at the first post-procedural imaging study as confirmed by the Imaging Core Lab.

Through 5 Years post-procedure
Incidence of Type I, II, III, IV or V Endoleaks
Lasso di tempo: Through 5 Years post-procedure

Incidence of Type I, II, III, IV or V Endoleaks defined as the persistence of blood flow outside the lumen of the stent-graft but within the native aorta or adjacent vascular segment being treated by the stent-graft as determined by the Imaging Core Lab.

Through 5 Years post-procedure

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Gretchen Wild, Terumo Aortic

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

20 gennaio 2021

Completamento primario (Stimato)

31 ottobre 2028

Completamento dello studio (Stimato)

31 ottobre 2028

Date di iscrizione allo studio

Primo inviato

10 dicembre 2020

Primo inviato che soddisfa i criteri di controllo qualità

5 gennaio 2021

Primo Inserito (Effettivo)

6 gennaio 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • IP-0021-20

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .